Levofloxacin Pharmacokinetics (PK) in the Severely Obese
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
Obesity is known to affect the concentrations of certain medications in the body.
Levofloxacin is a commonly used antibiotic. Based on what the investigators know about
levofloxacin and how it moves through the body, obesity may affect levofloxacin
concentrations. This study aims to show the effect of obesity on levofloxacin concentrations.
The hypothesis is as follows: A 750 mg intravenous (IV) dose of levofloxacin administered to
severely obese, critically ill patients will yield serum concentrations that are likely to be
therapeutic.